Beam Therapeutics (NasdaqGS:BEAM) launched BEAM-304, a new base-editing genetic medicine program for phenylketonuria, expanding its liver-targeted portfolio. The company entered a $500 million ...
Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the top gene therapy stocks to buy according to hedge funds. On February 25, ...
Beam Therapeutics is a leading biotech firm focused on precision genetic medicine with applications in hematology, immunology, oncology, and genetic diseases. Beam's stock assessment shows mixed ...
Beam Therapeutics recently announced that it secured a standby license with Kobe University and Bio Palette for key gene-editing patents and confirmed the upcoming resignation of board member Carole ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results